Biosimilar mAbs Enter the Evidence Era: Why Comparability Test Platforms Are Becoming Central to Regulatory Confidence NEWARK, DE / According to the latest market analysis by Future Market Insights, the biosimilar monoclonal antibody comparability test platforms market is entering a phase where analytical evidence is no longer supportive—it is decisive. Growth is being...